| Jansen J, Gaugris S, Bergman G, Sen SS. P339. Cost-effectiveness of Fasavance® in the treatment and prevention of osteoporosis in the United Kingdom. Osteoporos Int 2006;17(Suppl. 1):S96 | Conference abstract |
| Liu H, Michaud K, Nayak S, Karpf DB, Owens DK, Garber AM. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Int Med 2006;166:1209–17 | Excluded interventions |
| Boonen S. Impact of treatment efficacy and dosing frequency on cost-effectiveness of bisphosphonate treatment for osteoporosis: A perspective. Curr Med Res Opin 2009;25:2335–41 | Systematic review |
| Botteman MF, Meijboom M, Foley I, Stephens JM, Chen YM, Kaura S. Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom. Eur J Health Econ 2011;12:575–88 | Patients with renal cell carcinoma |
| Brandao CMR, Machado GPM, Acurcio FA. Pharmacoeconomic analysis of treatment strategies for osteoporosis in postmenopausal women: a systematic review. Rev Bras Reumatol 2012;52:924–37 | Systematic review |
| Cowell W, Koay A, Hunjan M. Economic analysis: ibandronate (Bonviva®) IV injection for the treatment of postmenopausal osteoporosis (PMO) in the UK. Value Health 2006;9:A380 | Conference abstract |
| Dell R, Greene D. Is osteoporosis disease management cost effective? Curr Osteoporos Rep 2010;8:49–55 | USA location |
| Fardellone P, Cortet B, Thomas T, Legrand E, Bresse X, Bisot-Locard S, et al. Cost-effectiveness simulation modeling of the compliance of 5 mg zoledronic acid once a year versus current treatments in post-menopausal osteoporosis. Value Health 2007;10:A395 | Conference abstract |
| Farquhar D, Pasquale M. Cost-effectiveness of risedronate versus ibandronate at one year: the case of the United Kingdom. J Bone Miner Res 2008;23:S212 | Conference abstract |
| Grima D, Borisov N. Cost-effectiveness of risedronate vs. generic alendronate: 1-year analysis among women 50–64 years old. J Bone Miner Res 2008;23:S212 | Conference abstract |
| Halperin M. The ethics of generics: medical and economic advantages of a generic alendronate in treating osteoporosis patients. Osteoporos Int 2006;17:S263 | Conference abstract |
| Hiligsmann M, Ethgen O, Bruyere O, Reginster J-Y. An economic evaluation of quantitative ultrasonometry as pre-screening test for the identification of patients with osteoporosis. Dis Manag Health Outcomes 2008;16:429–438 | Cost-effectiveness of a pretreatment scanning strategy |
| Hiligsmann M, Bruyere O, Ethgen O, Reginster J. Cost-effectiveness of bone densitometry screening combined with alendronate therapy for those who have osteoporosis. Value Health 2007;10:A236 | Conference abstract |
| Hiligsmann M, Kanis JA, Compston J, Cooper C, Flamion B, Bergmann P, et al. Health technology assessment in osteoporosis. Calcif Tissue Int 2013;93:1–14 | Systematic review |
| Jansen J, Gaugris S, Bergman G, Sen S. Cost-effectiveness of Fosavance® in the treatment and prevention of osteoporosis in the United Kingdom. Osteoporos Int 2006;17:S96 | Conference abstract |
| Jansen JP, Gaugris S, Bergman G, Sen SS, Jansen JP, Gaugris S, et al. Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and the Netherlands. Curr Med Res Opin 2008;24:671–84 | Excluded interventions |
| Johnell O. Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. PharmacoEconomics 2006;21:305–14 | Swedish location |
| Kanis J, Cooper C, Hiligsmann M, Rabenda V, Reginster JY, Rizzoli R. Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int 2011;22:2565–73 | Systematic review |
| Kanis JA, McCloskey EV, Jonsson B, Cooper A, Ström O, Borgström F. An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women. Arch Osteoporos 2010;5:19–48 | Excluded interventions |
| Kanis JA, McCloskey EV, Johansson H, Ström O, Borgström F, Oden A, et al. Case finding for the management of osteoporosis with FRAX–assessment and intervention thresholds for the UK. Osteoporos Int 2008;19:1395–408. [Erratum published in Osteoporos Int 2009;20:499–502] | Very limited discussion of modelling |
| Kanis JA, Adams J, Borgström F, Cooper C, Jonsson B, Preedy D, et al. Modelling cost-effectiveness in osteoporosis. Bone 2008;43:215–16 | Response to a letter published previously in the same journal |
| Logman F, Heeg B, Botteman M, Marfatia A, van Hout B. Cost-effectiveness of zoledronic acid in the prevention of fractures in postmenopausal women with early breast cancer receiving aromatase inhibitor: application to the United Kingdom. EJC Suppl 2007;5:156 | Conference abstract |
| Logman F, Heeg B, Botteman M, Kaura S, van Hout B. Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in post-menopausal women with early breast cancer receiving aromatase inhibitors in the United Kingdom. Cancer Res 2009;69:S574 | Conference poster |
| Logman J, Heeg B, Botteman M, Kaura S, van Hout B. Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in post-menopausal women with early-stage breast cancer receiving aromatase inhibitors in the United Kingdom. EJC Suppl 2008;6:69–70 | Conference abstract |
| Logman JF, Heeg BM, Botteman MF, Kaura S, van Hout BA, Logman JFS, et al. Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK. Ann Oncol 2010;21:1529–36 | Excluded intervention |
| Lynch N, Earnshaw S, Graham C, Middelhoven H. Cost-effectiveness of ibandronate injection IV in the treatment of UK women with postmenopausal osteoporosis who are intolerant to oral bisphosphonates. Osteoporos Int 2007;18:S11–12 | Conference abstract |
| Lynch N, Earnshaw S, Beard S, Cowell W. Ibandronate is cost-effective in the treatment of postmenopausal osteoporosis: a comparision of bisphosphonates. Osteoporos Int 2006;17:S11 | Conference abstract |
| Lynch N, Earnshaw S, Graham C, Patroe V, Boisdron J, Middelhoven H. Ibandronate IV injection is cost-effective in the treatment of UK women with postmenopausal osteoporosis who are intolerant to oral bisphosphonates. Ann Rheum Dis 2007;66:529 | Conference abstract |
| McLellan AR, Wolowacz SE, Zimovetz EA, Beard SM, Lock S, McCrink L, et al. Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int 2011;22:2083–98 | Cost-effectiveness assessment of methods of treatment delivery with same pharmaceuticals use in both arms |
| Olson M, Brereton N, Huels J, Roberts D, Akerhurst R. Comparison of the cost-effectiveness of zoledronic acid 5 mg for the management of post-menopausal osteoporosis in the UK setting. Value Health 2007;10:A395–6 | Conference abstract |
| Rizzoli R, Akesson K, Bouxsein M, Kanis J, Napoli N, Papapoulos S, et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2011;22:373–90 | Systematic review |
| Rosenzweig A, Mishra R. Evaluation and management of osteoporosis and fragility fractures in the elderly. Aging Health 2009;5:833–50 | Review of osteoporosis, prevention and treatment, no economic aspect |
| Simbula S, Burchini G, Santarlasci B, Trippoli S, Messori A. Cost-effectiveness analysis of therapeutic or preventive interventions <not enough value for money>. G Itali Farmacia Clin 2008;22:86–105 | Full-text paper not in the English language |
| Stevenson MD, Oakley JE, Lloyd JM, Brennan A, Compston JE, McCloskey EV, et al. The cost-effectiveness of an RCT to establish whether 5 or 10 years of bisphosphonate treatment is the better duration for women with a prior fracture. Med Dec Making 2009;29:678–89 | Establishing optimum duration of treatment |
| Stevenson MD, Jones ML, Stevenson MD, Jones ML. The cost effectiveness of a randomized controlled trial to establish the relative efficacy of vitamin K1 compared with alendronate. Med Dec Making 2011;31:43–52 | Excluded interventions |
| Sunyecz J, Silberman C, Poston S, Earnshaw S. Cost-effectiveness of ibandronate therapy for women with postmenopausal osteoporosis with respect to nonvertebral fracture efficacy. J Bone Miner Res 2008;23:S213 | Conference abstract |
| Warde N. Prostate cancer: is fracture prevention therapy cost-effective in patients with prostate cancer treated with ADT? Nature Rev Urol 2010;7:363 | In-brief article |
